Transaction · 0001628280-26-059884

Betz Stephen F.

Betz Stephen F., CSO, reported a transaction classified as return at Crinetics Pharmaceuticals, Inc. involving 79650.000000 shares for an estimated $6770250.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DCSO
CRNXCrinetics Pharmaceuticals, Inc.
Trade date
Sep 01, 2026
Filing date
Sep 01, 2026
View on SEC Insider profile
Estimated value-$6.77MShares × reported price
Shares traded79.6k$85.00 per share
Holdings after0Direct
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CRNX price since this filing

Daily closing prices, with the filing date and available return windows
CRNX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -1.7%1w ago -0.2%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
return
Code D
Identifier
0001628280-26-059884
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 01, 2026, 08:54 PM · 0d delay
Shares
79,650 sh
$85.00 per share
Estimated value
-$6.77M
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score

+10 points

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Scientific Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.

  2. F2

    Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceut…

  3. F3

    The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive…

  4. F4

    The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effectiv…

  5. F5

    The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Co…

Original filing · 0001628280-26-059884
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CRNX